Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
3
60%
Ph phase_3
1
20%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

unknown120%
not_yet_recruiting120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

NCT00864318
not_yet_recruitingphase_2

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

NCT07001618
completedphase_1

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

NCT02686346
completedphase_3

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

NCT00137995
unknownphase_2

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

NCT01857453

Clinical Trials (5)

Showing 5 of 5 trials
NCT00864318Phase 2

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Completed
NCT07001618Phase 2

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Not Yet Recruiting
NCT02686346Phase 1

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Completed
NCT00137995Phase 3

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Completed
NCT01857453Phase 2

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5